StockData
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc. (VRCA) stock

VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$2.85−0.29 (-9.08%)

Close on Nov 18, 2026Market cap $49.05MP/E –Yield –

Verrica Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Verrica Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $30.32M, up 106.2% year over year. For fiscal 2025 it was $35.58M, up 370.2% from the year before. The highest annual figure on record is $35.58M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$35.58M+370.2%
FY2024Dec 31, 2024$7.57M+47.7%
FY2023Dec 31, 2023$5.12M-43.3%
FY2022Dec 31, 2022$9.03M-24.7%
FY2021Dec 31, 2021$12.00M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.86M-53.8%
Q1 FY2026Mar 31, 2026$5.02M+46.1%
Q4 FY2025Dec 31, 2025$5.09M+1380.2%
Q3 FY2025Sep 30, 2025$14.34M–
Q2 FY2025Jun 30, 2025$12.70M+145.4%
Q1 FY2025Mar 31, 2025$3.44M-10.1%
Q4 FY2024Dec 31, 2024$344.00K-82.7%
Q3 FY2024Sep 30, 2024-$1.78M-161.1%
Q2 FY2024Jun 30, 2024$5.18M+2744.5%
Q1 FY2024Mar 31, 2024$3.83M+10240.5%
Q4 FY2023Dec 31, 2023$1.99M+2823.5%
Q3 FY2023Sep 30, 2023$2.92M-64.9%
Q2 FY2023Jun 30, 2023$182.00K-15.0%
Q1 FY2023Mar 31, 2023$37.00K-91.4%
Q4 FY2022Dec 31, 2022$68.00K–
Q3 FY2022Sep 30, 2022$8.32M–
Q2 FY2022Jun 30, 2022$214.00K–
Q1 FY2022Mar 31, 2022$431.00K-96.4%
Q4 FY2021Dec 31, 2021$0–
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$0–
Q1 FY2021Mar 31, 2021$12.00M–

More Verrica Pharmaceuticals figures

See a number that looks wrong?